Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:00310999 | Oral cavity | OSCC | regeneration | 114/7305 | 198/18723 | 8.54e-08 | 1.50e-06 | 114 |
GO:003812715 | Oral cavity | OSCC | ERBB signaling pathway | 76/7305 | 121/18723 | 9.59e-08 | 1.66e-06 | 76 |
GO:007084916 | Oral cavity | OSCC | response to epidermal growth factor | 37/7305 | 49/18723 | 2.21e-07 | 3.51e-06 | 37 |
GO:007136416 | Oral cavity | OSCC | cellular response to epidermal growth factor stimulus | 34/7305 | 45/18723 | 6.73e-07 | 9.53e-06 | 34 |
GO:000717315 | Oral cavity | OSCC | epidermal growth factor receptor signaling pathway | 67/7305 | 108/18723 | 1.04e-06 | 1.40e-05 | 67 |
GO:19011847 | Oral cavity | OSCC | regulation of ERBB signaling pathway | 50/7305 | 79/18723 | 1.06e-05 | 1.12e-04 | 50 |
GO:00420587 | Oral cavity | OSCC | regulation of epidermal growth factor receptor signaling pathway | 46/7305 | 73/18723 | 2.80e-05 | 2.59e-04 | 46 |
GO:19011858 | Oral cavity | OSCC | negative regulation of ERBB signaling pathway | 23/7305 | 32/18723 | 1.67e-04 | 1.14e-03 | 23 |
GO:00422464 | Oral cavity | OSCC | tissue regeneration | 42/7305 | 72/18723 | 6.89e-04 | 3.84e-03 | 42 |
GO:00480086 | Oral cavity | OSCC | platelet-derived growth factor receptor signaling pathway | 34/7305 | 56/18723 | 8.17e-04 | 4.35e-03 | 34 |
GO:000647023 | Oral cavity | EOLP | protein dephosphorylation | 72/2218 | 281/18723 | 1.19e-10 | 1.35e-08 | 72 |
GO:003109923 | Oral cavity | EOLP | regeneration | 50/2218 | 198/18723 | 1.30e-07 | 4.25e-06 | 50 |
GO:001631114 | Oral cavity | EOLP | dephosphorylation | 85/2218 | 417/18723 | 3.19e-07 | 9.47e-06 | 85 |
GO:00422462 | Oral cavity | EOLP | tissue regeneration | 22/2218 | 72/18723 | 1.82e-05 | 2.91e-04 | 22 |
GO:003812723 | Oral cavity | EOLP | ERBB signaling pathway | 31/2218 | 121/18723 | 2.21e-05 | 3.37e-04 | 31 |
GO:000717316 | Oral cavity | EOLP | epidermal growth factor receptor signaling pathway | 27/2218 | 108/18723 | 1.14e-04 | 1.27e-03 | 27 |
GO:007084923 | Oral cavity | EOLP | response to epidermal growth factor | 15/2218 | 49/18723 | 3.73e-04 | 3.38e-03 | 15 |
GO:190118422 | Oral cavity | EOLP | regulation of ERBB signaling pathway | 20/2218 | 79/18723 | 7.07e-04 | 5.78e-03 | 20 |
GO:190118522 | Oral cavity | EOLP | negative regulation of ERBB signaling pathway | 11/2218 | 32/18723 | 7.53e-04 | 6.05e-03 | 11 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTPN12 | SNV | Missense_Mutation | | c.824N>G | p.Ser275Cys | p.S275C | Q05209 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPN12 | SNV | Missense_Mutation | | c.263A>T | p.Tyr88Phe | p.Y88F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
PTPN12 | SNV | Missense_Mutation | | c.824N>T | p.Ser275Phe | p.S275F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPN12 | SNV | Missense_Mutation | rs766786152 | c.1427N>G | p.Ser476Cys | p.S476C | Q05209 | protein_coding | tolerated_low_confidence(0.08) | probably_damaging(0.91) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTPN12 | SNV | Missense_Mutation | | c.2063C>T | p.Ala688Val | p.A688V | Q05209 | protein_coding | deleterious(0) | benign(0.368) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PTPN12 | SNV | Missense_Mutation | | c.171N>C | p.Glu57Asp | p.E57D | Q05209 | protein_coding | deleterious(0.04) | benign(0.375) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTPN12 | insertion | Frame_Shift_Ins | novel | c.1281_1282insA | p.Leu430IlefsTer8 | p.L430Ifs*8 | Q05209 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPN12 | insertion | In_Frame_Ins | novel | c.1187_1188insCCAATTCTTTCTGTTTTA | p.Val396_Ser397insGlnPhePheLeuPheTyr | p.V396_S397insQFFLFY | Q05209 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPN12 | SNV | Missense_Mutation | | c.824C>T | p.Ser275Phe | p.S275F | Q05209 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PTPN12 | SNV | Missense_Mutation | | c.772G>C | p.Glu258Gln | p.E258Q | Q05209 | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |